Remdesivir COVID-19 Trials Posts Encouraging Results


In a comparative analysis published late last week in Clinical Infectious Diseases, the antiviral drug remdesivir was linked to significantly greater recovery and a 62% lower death rate by day 14 versus standard treatment in hospitalized adults with severe COVID-19. Researchers used data from 298 participants in an ongoing phase 3 trial of remdesivir at 45 international sites, as well as retrospective data from an ongoing real-world longitudinal study of 816 patients given standard treatment at 16 international sites.

Content Information

Content Author: 
Susan A Olender, Katherine K Perez, Alan S Go, Bindu Balani, Eboni G Price-Haywood, Nirav S Shah, MD, Su Wang, Theresa L Walunas, Shobha Swaminathan, Jihad Slim, BumSik Chin, Stéphane De Wit, Shamim M Ali, Alex Soriano Viladomiu, Philip Robinson et.al.

Content Source: 
Oxford Academic

Content Type: 
News